SCHEMBL98133

SCHEMBL98133

Cc1ncnc2nc[nH]c12.OC[C@H]1OC[C@H](O)[C@@H]1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.38
HTT P42858 3/20 0.38
LMNA P02545 2/20 0.38
CYP3A4 P08684 1/20 0.36
CYP1A2 P05177 2/20 0.36
CDK2 P24941 2/20 0.36
HIF1A Q16665 1/20 0.36
TSHR P16473 3/20 0.35
ALOX15 P16050 1/20 0.35
TP53 P04637 2/20 0.35
PDPK1 O15530 2/20 0.35
CHEK1 O14757 2/20 0.35
LRRK2 Q5S007 2/20 0.35
AURKA O14965 1/20 0.35
CHEK2 O96017 1/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
PRKACA P17612 1/20 0.35
CCNE1 P24864 1/20 0.35
MARK3 P27448 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hypoxanthine SCHEMBL4367641 0.86 LMNA (0.39) HSD17B10HTTLMNACYP3A4CYP1A2
SCHEMBL9396874 0.86 HTT (0.36) HSD17B10HTTLMNACYP3A4CYP1A2
SCHEMBL9142303 0.85 LMNA (0.38) HSD17B10HTTLMNACYP3A4CYP1A2
Adenine SCHEMBL593934 0.85 PI4KA (0.54) HSD17B10HTTLMNACYP3A4CYP1A2
Mercaptopurine Anhydrous SCHEMBL1998389 0.85 LMNA (0.38) HSD17B10HTTLMNACYP3A4CYP1A2
SCHEMBL4202116 0.85 CYP3A4 (0.45) HSD17B10HTTLMNACYP3A4CYP1A2
Dimethyladenine SCHEMBL1997329 0.85 CDK2 (0.57) HSD17B10HTTLMNACYP3A4CYP1A2
Ribose (Furanose) SCHEMBL1531264 0.81 HSD17B10 (0.40) HSD17B10HTTLMNACYP3A4CYP1A2
Ribose (Furanose) SCHEMBL12542065 0.81 HSD17B10 (0.40) HSD17B10HTTLMNACYP3A4CYP1A2
Ribose (Furanose) SCHEMBL1682946 0.81 HSD17B10 (0.40) HSD17B10HTTLMNACYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4388114-A1 CELL-TO-CELL DELIVERY OF RNA CIRCUITS California Institute of Technology (US) 2024-06-26 EP claimed
WO-2024124190-A1 ENGINEERED MICROORGANISMS FOR DELIVERY OF THERAPEUTIC AGENTS MICROBIAL MACHINES, INC. (US) 2024-06-13 WO claimed
EP-4370686-A1 STOICHIOMETRIC EXPRESSION OF MESSENGER POLYCISTRONS California Institute of Technology (US) 2024-05-22 EP claimed
WO-2024081912-A1 PROTEIN-BASED SIGNAL AMPLIFICATION CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-04-18 WO claimed
US-20240018513-A1 SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION FRED HUTCHINSON CANCER CENTER (US) 2024-01-18 US claimed
EP-4305179-A2 ACOUSTIC REMOTE CONTROL OF MICROBIAL IMMUNOTHERAPY California Institute of Technology (US) 2024-01-17 EP claimed
WO-2024011146-A1 A SYNTHETIC PROTEIN-LEVEL NEURAL NETWORK IN MAMMALIAN CELLS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2024-01-11 WO claimed
EP-4232577-A1 SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION Fred Hutchinson Cancer Center (US) 2023-08-30 EP claimed
WO-2023070134-A2 SYNTHETIC INTRONS FOR TARGETED GENE EXPRESSION FRED HUTCHINSON CANCER CENTER (US) 2023-04-27 WO claimed
US-20230103980-A1 THERMAL STATE SWITCHES IN MACROPHAGES CALIFORNIA INSTITUTE OF TECHNOLOGY 2023-04-06 US claimed
US-7820184-B2 Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders GENELUX CORPORATION (US) 2010-10-26 US claimed
US-7662398-B2 anticancer treatment by administering a recombinant vaccina virus of a modified TK thymidine kinase and hemagglutinin gene; virus does not accumulate to toxic levels in non-targeted organs; kits GENELUX CORPORATION (US) 2010-02-16 US claimed
US-7588771-B2 Microorganisms for therapy GENELUX CORPORATION (US) 2009-09-15 US claimed
US-20090180987-A1 Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders GENELUX CORPORATION 2009-07-16 US claimed
EP-2028270-A2 Modified recombinant vaccina viruses and uses thereof Genelux Corporation (US) 2009-02-25 EP claimed
EP-1644492-B1 MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF GENELUX CORP (US) 2009-01-07 EP claimed
US-20070025981-A1 anticancer treatment by administering a recombinant vaccina virus of a modified TK thymidine kinase and hemagglutinin gene; virus does not accumulate to toxic levels in non-targeted organs; kits GENELUX CORPORATION 2007-02-01 US claimed
US-20060051370-A1 anticancer treatment by administering a recombinant vaccina virus of a modified TK thymidine kinase and HA hemagglutinin gene; virus does not accumulate to toxic levels in non-targeted organs GENELUX CORPORATION 2006-03-09 US claimed
US-5902740-A Process for the decontamination of cell cultures containing mycoplasmas BEHRINGWERKE AKTIENGESELLSCHAFT (DE) 1999-05-11 US claimed
US-4387161-A INCUBATION WITH 6-METHYLPURINE DEOXYRIBOSIDE; ANTIGROWTH AGENTS; CYTOLYSIS INSTITUTE FOR MEDICAL RESEARCH (US) 1983-06-07 US claimed